Definium Therapeutics, Inc. DFTX
33.27 USD +2.91 (+9.58%)
At closeNov 9, 2026, 6:38 AM EST
32.00 -1.27 -3.82%
Pre-market · Nov 9, 6:38 AM ET
30.91 Day range 33.42
10.47 52-week range 49.70
- YTD
- +148.47%
- 1 year
- +193.39%
News
businesswire.com Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress NEW YORK--(BUSINESS WIRE)-- #ClinicalTrials--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of…
businesswire.com Definium Therapeutics to Participate at Upcoming Investor Conferences NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics…
benzinga.com JP Morgan Initiates Coverage On Definium Therapeutics with Overweight Rating, Announces Price Target of $84 JP Morgan initiates coverage on Definium Therapeutics (NASDAQ:DFTX) with a Overweight rating and announces Price Target of $84.